{"paper_id":"2001c691-8d08-4bd8-89fa-e4fce32ed2c2","body_text":"Abstract\nMass spectrometry-based proteomic profiling of cerebrospinal fluid (CSF) in large patient cohorts, particularly among childhood cancer survivors, remains scarce, limiting opportunities for benchmarking, method development, and validation. Here, we present a longitudinal CSF proteomics dataset from survivors of childhood acute lymphoblastic leukemia (ALL). Samples were collected from 178 patients enrolled in the TOTXVI therapeutic protocol at two timepoints: diagnosis (pre-treatment) and during the consolidation phase of chemotherapy (totaling 356 samples). CSF proteomes were profiled using tandem-mass-tag (TMT) labeling coupled with extensive fractionation and high-resolution liquid chromatography-tandem mass spectrometry (LC/LC-MS/MS). The dataset includes quantitative profiles for more than 3,000 confidently identified unique proteins. This resource enables the investigation of chemotherapy-induced alterations in the CSF proteome and provides a valuable resource for studying the molecular mechanisms of neurotoxicity, identifying biomarkers of adverse late effects, and guiding the development of neuroprotective strategies in childhood cancer survivors.\nCompeting Interest Statement\nThe authors have declared no competing interest.","source_license":"CC-BY-4.0","license_restricted":false}